David Egging

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

Ronald C. Elgersma, Ruud G. E. Coumans, Tijl Huijbregts et al. · Molecular Pharmaceutics · 2015 · 219 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink et al. · Molecular Cancer Therapeutics · 2015 · 215 citations

Pharmacy, Oncology, Pharmacology +16

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim H.A. Dokter, Ruud Ubink, Miranda van der Lee et al. · Molecular Cancer Therapeutics · 2014 · 163 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Interactions of human tenascin-X domains with dermal extracellular matrix molecules

David Egging, Franka van den Berkmortel, Glen Taylor et al. · Archives of Dermatological Research · 2006 · 63 citations

Life Sciences, Cell Biology, Molecular Biology +14

Wound Healing in Tenascin-X Deficient Mice Suggests that Tenascin-X is Involved in Matrix Maturation Rather than Matrix Deposition

David Egging, Ivonne van Vlijmen‐Willems, Tomas van Tongeren et al. · Connective Tissue Research · 2007 · 60 citations

Veterinary Medicine, Pathobiology, Pathology +15